Which countries have flagged quality issues or recalls for generic ivermectin products?

1. What the records actually show about ivermectin and recalls

Official recall coverage in the supplied results is dominated by food, pet food and consumer-product recalls; there is no item among the provided recall notices that names a country recalling generic human ivermectin tablets or suspending a manufacturer for quality issues ^{[4] [5] [6]}. The U.S. FDA material included in the results discusses ivermectin safety and misuse in the context of COVID‑19 and warns about overdose risks, but that document does not announce recalls of generic human ivermectin products ^[1].

2. Regulatory tone: warnings about inappropriate use, not product recalls

Regulators and mainstream medical reporting in the sample emphasize that ivermectin is approved for parasitic infections and caution against unproven uses such as COVID‑19; for example, the FDA notes it has not authorized ivermectin for COVID‑19 and lists overdose harms, rather than announcing quality recalls ^[1]. News outlets summarize that research did not support ivermectin for COVID‑19 and that political moves have loosened access in some U.S. states ^{[2] [7]}.

3. Global context in the supplied reporting: availability and demand, not defective batches

Several pieces in the dataset explain ivermectin’s status as a widely available generic with many manufacturers and increased demand since the pandemic; that market pressure can raise concerns about quality in general, but the specific search results show market reports and clinical debate rather than documented national recalls ^{[8] [3]}. Where medicine regulators have acted in other countries on ivermectin use (e.g., revoking compassionate programs), the cited material discusses policy, not recalls of product lots ^[9].

4. What a reader should not conclude from these sources

Do not infer from the absence of recall notices here that quality problems have never occurred worldwide; the materials provided simply do not contain reports of countries flagging or recalling generic ivermectin lots. The correct statement, based on the supplied sources, is that “available sources do not mention” any country-level recalls or quality flags for generic human ivermectin products ^{[1] [3] [8]}.

5. Why confusion often arises around ivermectin

The supplied reporting shows two recurring drivers of confusion: (a) high public interest and politicization of ivermectin after pandemic debates, which led to legislation and increased prescriptions in some U.S. states ^{[2] [7]}, and (b) a proliferation of claims about off‑label benefits (cancer, COVID‑19) that prompted scrutiny and debunking from mainstream medical sources ^{[2] [10]}. Those dynamics can make consumers conflate warnings about misuse with regulatory recalls of manufacturing quality—yet the sources here separate those topics ^{[1] [3]}.

6. If you need definitive recall tracking, go to regulators

For verified, current dossiers on product recalls, the most reliable sources are national regulators and their recall bulletins (FDA, EMA, national medicines agencies) or consolidated recall aggregators; none of the search results supplied a regulator notice announcing a recall for generic human ivermectin, so consult those agencies directly for live, authoritative recall lists ^{[4] [11]}. The eFoodAlert links in the dataset show how recall aggregators work for food and consumer recalls but do not substitute for medicines regulators when checking drug recalls ^{[12] [11]}.

7. Bottom line and next steps

Based on the material provided, no country is named as having flagged quality issues or initiated recalls of generic human ivermectin products in these search results—available sources do not mention any such recalls ^{[1] [3]}. If you want confirmation beyond this dataset, check the FDA, EMA, and national medicines regulator recall pages or request me to search those specific agencies’ databases in a fresh query.